Treatment Modification and Symptom Burden in High-Risk Dialysis Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- The Rogosin Institute
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Number of Participants Recruited, Consented, Randomized and Completed
Study Overview
Brief Summary
Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •hemodialysis patient
- •transplant ineligible
Exclusion Criteria
- •unable to answer questionnaires for any reason
Outcomes
Primary Outcomes
Number of Participants Recruited, Consented, Randomized and Completed
Time Frame: Each participant was assessed for 6 weeks; total recruitment period was 15 months
Secondary Outcomes
- Symptom Burden(Baseline and 6 weeks)